243 related articles for article (PubMed ID: 25490875)
1. Increasing time to treatment initiation for head and neck cancer: an analysis of the National Cancer Database.
Murphy CT; Galloway TJ; Handorf EA; Wang L; Mehra R; Flieder DB; Ridge JA
Cancer; 2015 Apr; 121(8):1204-13. PubMed ID: 25490875
[TBL] [Abstract][Full Text] [Related]
2. Increased pathologic upstaging with rising time to treatment initiation for head and neck cancer: A mechanism for increased mortality.
Xiao R; Ward MC; Yang K; Adelstein DJ; Koyfman SA; Prendes BL; Burkey BB
Cancer; 2018 Apr; 124(7):1400-1414. PubMed ID: 29315499
[TBL] [Abstract][Full Text] [Related]
3. Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer.
David JM; Ho AS; Luu M; Yoshida EJ; Kim S; Mita AC; Scher KS; Shiao SL; Tighiouart M; Zumsteg ZS
Cancer; 2017 Oct; 123(20):3933-3942. PubMed ID: 28640546
[TBL] [Abstract][Full Text] [Related]
4. Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States.
Murphy CT; Galloway TJ; Handorf EA; Egleston BL; Wang LS; Mehra R; Flieder DB; Ridge JA
J Clin Oncol; 2016 Jan; 34(2):169-78. PubMed ID: 26628469
[TBL] [Abstract][Full Text] [Related]
5. The impact of time to treatment initiation on survival from head and neck cancer in north-eastern Italy.
Polesel J; Furlan C; Birri S; Giacomarra V; Vaccher E; Grando G; Gobitti C; Navarria F; Schioppa O; Minatel E; Bidoli E; Barzan L; Franchin G
Oral Oncol; 2017 Apr; 67():175-182. PubMed ID: 28351574
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Chemoradiation After Surgical Resection in Elderly Patients With High-Risk Squamous Cell Carcinoma of the Head and Neck: A National Cancer Database Analysis.
Woody NM; Ward MC; Koyfman SA; Reddy CA; Geiger J; Joshi N; Burkey B; Scharpf J; Lamarre E; Prendes B; Adelstein DJ
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):784-792. PubMed ID: 28602410
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base.
Amini A; Jones BL; McDermott JD; Serracino HS; Jimeno A; Raben D; Ghosh D; Bowles DW; Karam SD
Cancer; 2016 May; 122(10):1533-43. PubMed ID: 26969811
[TBL] [Abstract][Full Text] [Related]
8. Association of Medicaid Expansion Under the Affordable Care Act With Stage at Diagnosis and Time to Treatment Initiation for Patients With Head and Neck Squamous Cell Carcinoma.
Sineshaw HM; Ellis MA; Yabroff KR; Han X; Jemal A; Day TA; Graboyes EM
JAMA Otolaryngol Head Neck Surg; 2020 Mar; 146(3):247-255. PubMed ID: 31944232
[TBL] [Abstract][Full Text] [Related]
9. Utilization and Survival of Postoperative Radiation or Chemoradiation for pT1-2N1M0 Head and Neck Cancer.
Lee A; Givi B; Roden DF; Tam MM; Wu SP; Gerber NK; Hu KS; Schreiber D
Otolaryngol Head Neck Surg; 2018 Apr; 158(4):677-684. PubMed ID: 29256329
[TBL] [Abstract][Full Text] [Related]
10. Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer.
Zumsteg ZS; Kim S; David JM; Yoshida EJ; Tighiouart M; Shiao SL; Scher K; Mita A; Sherman EJ; Lee NY; Ho AS
Cancer; 2017 May; 123(9):1555-1565. PubMed ID: 28001302
[TBL] [Abstract][Full Text] [Related]
11. Delays in definitive cervical cancer treatment: An analysis of disparities and overall survival impact.
Ramey SJ; Asher D; Kwon D; Ahmed AA; Wolfson AH; Yechieli R; Portelance L
Gynecol Oncol; 2018 Apr; 149(1):53-62. PubMed ID: 29605051
[TBL] [Abstract][Full Text] [Related]
12. Quality metrics for head and neck cancer treated with definitive radiotherapy and/or chemotherapy.
Elsharawi R; Antonucci E; Sukari A; Cramer JD
Head Neck; 2021 Jun; 43(6):1788-1796. PubMed ID: 33594736
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database.
Ko HC; Chen S; Wieland AM; Yu M; Baschnagel AM; Hartig GK; Harari PM; Witek ME
Head Neck; 2017 Nov; 39(11):2159-2170. PubMed ID: 28737019
[TBL] [Abstract][Full Text] [Related]
14. Association of Facility Volume With Positive Margin Rate in the Surgical Treatment of Head and Neck Cancer.
Nocon CC; Ajmani GS; Bhayani MK
JAMA Otolaryngol Head Neck Surg; 2018 Dec; 144(12):1090-1097. PubMed ID: 30347018
[TBL] [Abstract][Full Text] [Related]
15. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy.
Strongin A; Yovino S; Taylor R; Wolf J; Cullen K; Zimrin A; Strome S; Regine W; Suntharalingam M
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1823-30. PubMed ID: 21549516
[TBL] [Abstract][Full Text] [Related]
16. Beyond Positive Margins and Extracapsular Extension: Evaluating the Utilization and Clinical Impact of Postoperative Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer.
Trifiletti DM; Smith A; Mitra N; Grover S; Lukens JN; Cohen RB; Read P; Mendenhall WM; Lin A; Swisher-McClure S
J Clin Oncol; 2017 May; 35(14):1550-1560. PubMed ID: 28475848
[TBL] [Abstract][Full Text] [Related]
17. Adult soft tissue sarcoma and time to treatment initiation: An analysis of the National Cancer Database.
Curtis GL; Lawrenz JM; George J; Styron JF; Scott J; Shah C; Shepard DR; Rubin B; Nystrom LM; Mesko NW
J Surg Oncol; 2018 Jun; 117(8):1776-1785. PubMed ID: 29949654
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of time trends in treatment of head and neck squamous cell carcinoma.
Balchander D; Shorbaji K; Cabrera CI; Hoying D; Clancy K; Fowler N; Thuener JE; Lavertu P; Pan Q; Teknos TN; Rezaee RP; Li S; Tamaki A
Am J Otolaryngol; 2023; 44(6):103966. PubMed ID: 37481899
[TBL] [Abstract][Full Text] [Related]
19. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
Chang CL; Yuan KS; Wu SY
Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614
[TBL] [Abstract][Full Text] [Related]
20. Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients.
Descamps G; Karaca Y; Lechien JR; Kindt N; Decaestecker C; Remmelink M; Larsimont D; Andry G; Hassid S; Rodriguez A; Khalife M; Journe F; Saussez S
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2185-96. PubMed ID: 27370781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
